BrainCheck

We're thrilled to announce the launch of BrainCheck® Population Analytics, a new solution that securely analyzes your organization's existing EHR data and returns a prioritized registry of patients whose records show patterns warranting further cognitive evaluation. This makes proactive outreach and cognitive care possible at a population level, without waiting for the next Annual Wellness Visit. "The analysis gave us a comprehensive view of our patient population and a prioritized patient registry that showed us exactly where to begin. By working from a simple structured EHR data extract, we gained that level of visibility within weeks, without disrupting our EHR roadmap or incurring significant implementation costs.” — Ronnie Castello, Chief Operating Officer, Capital Medical Center Population Analytics does not diagnose any condition or replace clinical judgment; it organizes existing EHR data to give clinicians a starting point for review. Read the full announcement here: https://lnkd.in/gBqhEXQp

Congratulations to Dr. Dag Aarsland, scientific lead of the PREDICTOM IHI Project, on receiving the Inge Grundke-Iqbal Award for Alzheimer's Research at AAIC 2026. BrainCheck is proud to be part of the PREDICTOM study alongside Dr. Aarsland, and we're excited to see his work recognized.

We're heading to AAIC 2026 in London next week with three accepted poster presentations! The research covers: - Clinical validation of BrainCheck Assess against the MoCA - Real-world outcomes from our cognitive care planning tool across more than 2,400 patients and multiple clinical practices - Multilingual adaptation of BrainCheck Assess across five European languages through the PREDICTOM initiative. Each of these studies reflects the clinical rigor we hold ourselves to at BrainCheck, validating our tools against established instruments, testing them in real patient populations, and contributing to the evidence base this field needs. Read the full press release: https://lnkd.in/g3k7u3vD

Information #fusionmodels can improve #earlydetection of dementia. This project is led by the a2 Collective #awardee BrainCheck. They are collaborating with their AITC partner #jhaitc. Principal investigators Bin Huang and Edison Thomaz are leading this important work. They are building information fusion models to detect cognitive decline. This pilot project focuses on critical needs in #dementiacare. The team utilizes advanced #machinelearning methods to achieve this. The goal is to improve #clinicaloutcomes for older adults. This technology supports independent living and reduces caregiver burden. https://lnkd.in/gbxV4fb7

For the first time, a complete pathway from early detection to treatment exists for Alzheimer's disease, and primary care sits at the front of it. In yesterday's webinar, Phyllis Ferrell sat down with BrainCheck Chief Medical Officer Stephen Bekanich, M.D. to walk through what changed in early 2026, what's ready to use in practice today, and how to connect digital cognitive assessment, blood-based biomarkers, and anti-amyloid therapy into a real PCP workflow. You can watch the recording here: https://lnkd.in/gKEa_BaW

Three major developments in early 2026 are changing how clinicians identify and act on cognitive decline. Are you up to speed? Join us Tuesday, May 12th at 11 AM ET for The New Science of Early Detection webinar, where Stephen Bekanich, M.D., Chief Medical Officer at BrainCheck, breaks down what's changed, what's ready for practice today, and how to connect it all in a real PCP workflow — moderated by Phyllis Ferrell of PBFerrell LLC. You'll walk away understanding: - Why 95% of PCPs want digital cognitive assessments but most still aren't using them, and what changes that - What the Alzheimer's Association and CEOi blood-based biomarker guideline means — and what it doesn't yet cover for primary care - The state of anti-amyloid therapy in 2026, including real-world persistence data and the expanding treatment landscape - How the MCI window defines your opportunity — and why timing in the detection sequence is everything Secure your seat today: https://bit.ly/4tSjMiF

The science of brain health is moving fast. That's why we created Insights & Implications in Brain Health, our new clinical digest translating the latest research into what it actually means for primary care. Here's what's covered in this issue: 1. Blood-based biomarkers: new AA guideline on when and how to use them 2. Digital cognitive assessment: 95% of PCPs want to adopt — barriers remain operational 3. Anti-amyloid therapies: real-world persistence data and what's next 4. Care planning in ADRD: ACP reduces costs and hospitalizations 5. Modifiable risk factors: 45% of dementia may be preventable 6. Caregiver support: structured interventions reduce burden and isolation Read more about the latest science and what it means for your patients today: https://lnkd.in/gX-wcYcQ

Neurologists in outpatient practice routinely care for patients with very different clinical needs. In a new clinical case study from MIND Neurology Clinic, Jontel Pierce, MD, shares how she uses BrainCheck Assess as a consistent standard across three different patient populations: - Mild Cognitive Impairment & Alzheimer's Disease — establishing objective baselines and tracking disease trajectory every 6–9 months - Concussion & TBI — serial assessments over the course of recovery - Adult ADHD — capturing pre-treatment baselines to evaluate treatment response over time Read the clinical case study: https://lnkd.in/gv8eHE6P

We're proud to share the publication of a peer-reviewed study design paper for PREDICTOM — the large-scale European Alzheimer's early detection initiative in which BrainCheck Assess is serving as a cognitive assessment tool. The paper, published in The Journal of Prevention of Alzheimer's Disease, details the full protocol for a novel AI-driven screening platform designed to bring Alzheimer's diagnostics into the home and community care setting. "With disease-modifying therapies now approved for early-stage Alzheimer's, the window for meaningful intervention is earlier than ever, and that makes scalable, accessible screening tools absolutely critical." -Mary Patterson, Vice President of Clinical Operations at BrainCheck Read the full press release here: https://lnkd.in/gYTbCWdM

Robert Todd Hurst, MD, FACC, FASE, co-founder of HealthspanMD, is a nationally recognized preventive cardiologist and longevity expert with nearly 30 years of experience. Alongside co-founder Lisa M Hurst, MD, a board-certified internal medicine physician with 25 years experience, they built HealthspanMD to move beyond reactive care and focus on prevention, early detection, and long-term vitality. BrainCheck Assess gave HealthspanMD Preventive Cardiology what their model demands: standardized, objective cognitive data that benchmarks patients over time. Read more here: https://bit.ly/4mOkqLA